Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqCM - Nasdaq Real Time Price USD

Vistagen Therapeutics, Inc. (VTGN)

Compare

2.3900

+0.0500

+(2.14%)

At close: 4:00:00 PM EDT

2.3800

-0.01

(-0.42%)

After hours: 4:58:30 PM EDT

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

SOUTH SAN FRANCISCO, Calif., March 19, 2025--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at the Anxiety and Depression Association of America (ADAA) Conference in Las Vegas, Nevada from April 3 to 5, 2025. The Company’s poster presentations will explore the age of onset of social anxiety disord

Business Wire 14 days ago

VTGN
+2.14%
Vistagen to Participate in Stifel 2025 Virtual CNS Forum

SOUTH SAN FRANCISCO, Calif., March 04, 2025--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that management will participate in Stifel’s 2025 Virtual CNS Forum.

Business Wire 29 days ago

VTGN
+2.14%
Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

SOUTH SAN FRANCISCO, Calif., February 20, 2025--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, will present at the 45th Annual TD Cowen Healthcare Conference.

Business Wire last month

VTGN
+2.14%
Vistagen Therapeutics Third Quarter 2025 Earnings: Beats Expectations

Vistagen Therapeutics ( NASDAQ:VTGN ) Third Quarter 2025 Results Key Financial Results Net loss: US$14.1m (loss widened...

Simply Wall St. last month

VTGN
+2.14%
Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlights: Promising Trial Results and ...

Vistagen Therapeutics Inc (VTGN) reports positive Phase 3 trial outcomes and financial stability, despite rising operational costs and market competition.

GuruFocus.com last month

VTGN
+2.14%
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates

VistaGen Therapeutics (VTGN) delivered earnings and revenue surprises of 8% and 35%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

VTGN
+2.14%
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

SOUTH SAN FRANCISCO, Calif., February 13, 2025--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2025 third quarter ended December 31, 2024, and provided a corporate update.

Business Wire last month

VTGN
+2.14%
Companies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. last month

VTGN
+2.14%
Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025

SOUTH SAN FRANCISCO, Calif., February 06, 2025--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, February 13, 2025 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 third quarter ended December 31, 2024, and provide

Business Wire last month

VTGN
+2.14%
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

SOUTH SAN FRANCISCO, Calif., February 05, 2025--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that the U.S. Patent and Trademark Office (USPTO) granted a patent to the Company for its oral non-opioid product candidate, AV-101, for the treatment of neuropathic pain. The patent will not expire until at least 2034 and is part of Vistag

Business Wire last month

VTGN
+2.14%
Vistagen reports positive outcomes from Phase IIA cancer cachexia trial

Patients treated with the spray reported an improvement of 71% in the subjective feeling of hunger (SFH).

Clinical Trials Arena 2 months ago

VTGN
+2.14%
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

SOUTH SAN FRANCISCO, Calif., January 14, 2025--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced positive results from an exploratory Phase 2A study of PH284 in cancer cachexia. PH284 is an investigational pherine nasal spray differentiated from all current treatments for the loss of appetite associated with chronic disorders, such as cancer. In the study, PH284 demonstrated higher mean subjective fe

Business Wire 2 months ago

VTGN
+2.14%
Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

SOUTH SAN FRANCISCO, Calif., January 10, 2025--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in a repeat dose study of fasedienol, its investigational neuroactive pherine nasal spray in Phase 3 development for the acute treatment of social anxiety disorder (SAD).

Business Wire 2 months ago

VTGN
+2.14%
Vistagen to Present at the Stifel 2024 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., November 14, 2024--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that company management will present and host one-on-one meetings during the Stifel 2024 Healthcare Conference taking place November 18 and 19, 2024 in New York City.

Business Wire 4 months ago

VTGN
+2.14%
Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ...

Despite increased expenses and net loss, Vistagen Therapeutics Inc (VTGN) advances its neuroscience pipeline with promising clinical trials and robust financial backing.

GuruFocus.com 4 months ago

VTGN
+2.14%
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates

VistaGen Therapeutics (VTGN) delivered earnings and revenue surprises of -5% and 45.37%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 4 months ago

VTGN
+2.14%
Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

SOUTH SAN FRANCISCO, Calif., November 07, 2024--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year 2025 second quarter ended September 30, 2024, and provided a corporate update.

Business Wire 4 months ago

VTGN
+2.14%
Vistagen to Present at the 2024 Neuroscience Education Institute Congress

SOUTH SAN FRANCISCO, Calif., November 05, 2024--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that it will present posters highlighting new prevalence data for social anxiety disorder (SAD), an indication for which fasedienol, its lead intranasal pherine product candidate, is in U.S. registration-directed Phase 3 development for the acute treatment of the disorder, and two additional non-systemic

Business Wire 4 months ago

VTGN
+2.14%
Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024

SOUTH SAN FRANCISCO, Calif., November 01, 2024--Vistagen (NASDAQ: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced it will host a conference call and webcast on Thursday, November 7, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 second quarter ended September 30, 2024, and provide a corporate update.

Business Wire 4 months ago

VTGN
+2.14%
VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know

VistaGen Therapeutics (VTGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 5 months ago

VTGN
+2.14%

Performance Overview

Return	VTGN	S&P 500 (^GSPC)
YTD	-18.98%	-3.58%
1-Year	-55.74%	+8.94%
3-Year	-93.07%	+24.75%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Vistagen Therapeutics, Inc. (VTGN)

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

Vistagen to Participate in Stifel 2025 Virtual CNS Forum

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

Vistagen Therapeutics Third Quarter 2025 Earnings: Beats Expectations

Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlights: Promising Trial Results and ...

VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

Companies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In Growth

Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

Vistagen reports positive outcomes from Phase IIA cancer cachexia trial

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

Vistagen to Present at the Stifel 2024 Healthcare Conference

Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ...

VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates

Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

Vistagen to Present at the 2024 Neuroscience Education Institute Congress

Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024

VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know

Performance Overview